Loading asset research
Vor Biopharma Inc. Common Stock
VORNasdaq · USD · StocksQuote as of · Exchange session not verified$22.30
-0.18%
Today
VOR
Loading 1D prices…
Market cap
$1.3B
Volume
800.4K
52w high
$49.9552w low
$6.50Company profile
Vor Biopharma Inc. Common Stock
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
76
Fiscal year end
1231
CIK
1817229
Session & valuation
Open$22.83
Previous close$22.34
Day high$23.47
Day low$22.20
30-day avg. volume741.4K
Outstanding shares59.2M
Diluted EPS-$70.50
Latest annual period
P/E (trailing)0.12
P/E (forward)-5.85
Price / book-6.07
Beta1.72
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| IMTXImmatics N.V. Ordinary Shares | $1.3B | — | — | -$1.61 | +0.46% | Buy |
| MAZEMaze Therapeutics Inc. Common Stock | $1.4B | $0.00 | — | -$3.05 | -0.89% | Buy |
| CGEMCullinan Therapeutics Inc. Common Stock | $1.3B | $0.00 | — | -$3.36 | -2.05% | Buy |
| MGTXMeiraGTx Holdings plc Ordinary Shares | $1.2B | $81.4M | -140.31% | -$1.42 | -0.43% | Buy |
| REPLReplimune Group Inc. Common Stock | $1.2B | $0.00 | — | -$3.38 | -2.34% | Buy |